NIAID is focused on finding new and more effective therapies, drug classes, and antiretroviral drug combinations that can extend and improve the quality of life for people infected with HIV/AIDS and associated co-infections and complications. NIAID supports research that advances our understanding of HIV and how it causes disease, thereby unlocking new targets for drug development. The goal is to identify new drugs that are less toxic with fewer side effects, promote better adherence, and are readily accessible, particularly in resource-limited settings. Promising medicines are tested in human clinical trials to determine whether they are safe and effective.
Several therapeutic agents have been developed to treat the diseases caused by HIV and its co-infections and to prevent maternal-child transmission of HIV. The Food and Drug Administration (FDA) maintains a current listing of HIV/AIDS therapeutics that have been approved for public use.
NIAID’s HIV/AIDS therapeutics research agenda is guided by the National Institutes of Health (NIH) Office of AIDS Research, the entity responsible for the overall scientific, budgetary, legislative, and policy elements of all AIDS research sponsored by NIH. The major areas of research within NIAID's therapeutic research agenda include
Last Updated September 11, 2013